A 21-year-old male with a thyroid condition noticed his hair thinning uniformly without a receding hairline. He is considering using a 5ARI to prevent further baldness if he starts TRT.
A hair transplant of 3361 grafts, 11.5 months after the procedure, that resulted in a very natural looking NW1 hairline; the person who underwent this procedure has not experienced any hair loss and is expecting to have no future hairloss either.
Dutasteride can cause hair shedding even with suppressed testosterone levels due to previous damage from DHT. Hair shedding is often a sign of damaged hair being replaced by healthier growth.
Hair follicle regenerative therapy is being developed, with clinical trials planned in Japan, potentially allowing for hair cloning and eliminating the need for treatments like finasteride. If successful, the treatment could be available in Japan by 2025, but widespread access and affordability may take longer.
The conversation is about someone planning to start finasteride or RU58841 for hair loss and wanting to know which hormones to test beforehand. They found a package for testing testosterone, free testosterone, estradiol, and DHT, and are asking if these tests are enough.
Pelage PP405 is a new hair loss treatment in trials, potentially reactivating dormant hair follicles without affecting hormones. Results are expected in February 2025, offering an alternative to minoxidil and finasteride.
A user ordered Alpha Plus from Anagenica, expecting it to contain specific percentages of Fin, Estradiol, Minoxidil, and CB0301. However, the received product's label showed different percentages, including a surprising 25% CB, leading the user to question its safety and accuracy.
A user discusses their habit of analyzing others' hair due to their own hair thinning at 18. Another user mentions starting finasteride in 2010 and still having a full head of hair.
The post and conversation are about the role of the enzyme 3alpha-hydroxysteroid reductase in hair loss and the potential of compounds like procyanidin B2 and sulforaphane to boost its activity for hair regrowth. Further research is needed to develop effective treatments based on this theory.
A dermatologist checked for hereditary hair loss using blood tests and plans to perform a trichogram. The user had slightly low Vitamin D3 levels, and the trichogram may help confirm androgenetic alopecia.
The conversation discusses a new liposomal topical finasteride from Hasson and Wong, available in Canada and Italy, soon in the US, costing $40/month. It claims to reduce scalp DHT by 50% without affecting serum DHT, potentially benefiting those who can't tolerate oral finasteride or RU58841.
The post discusses a successful hair loss treatment involving a hair transplant, finasteride, and minoxidil. The user underwent a 2000 graft hair transplant at the hairline in a clinic in Sweden.
Hormone replacement therapy with spironolactone and estradiol significantly improved hair thickness and growth, surpassing previous treatments like dutasteride, finasteride, and minoxidil. The user experienced regrowth in receded areas and a more youthful appearance.
The user is experiencing hair loss after a hair transplant and is considering using fluridil (Eucapil) and possibly alfatradiol as treatments, as they couldn't tolerate finasteride or minoxidil. The manufacturer of Eucapil confirmed they won't produce higher concentrations due to lack of efficacy.
PP-405, a potential hair loss treatment, shows promise in stimulating dormant hair follicles and may help with various hair loss types. Current treatments like Minoxidil are still recommended as PP-405 is in early trials and may take years to become available.
Exploring treatment options for male pattern baldness, including minoxidil, finasteride, and RU58841, with a focus on Eucapil, a topical agent. The post also discusses research from various sources about the efficacy of these treatments.
Increased Malassezia and Cutibacterium in the scalp microbiome are linked to higher sebum production and inflammation in androgenetic alopecia (AGA). Treatments include ciclopirox shampoo, benzoyl peroxide shampoo, clobetasol propionate, calcipotriol, minoxidil, finasteride, and dutasteride.
Hair loss treatments, including PP405, minoxidil, finasteride, and RU58841, with hopes for future solutions. Participants discuss the emotional impact of hair loss and consider alternatives like hair transplants or acceptance.
The conversation discusses the progress of Clascoterone (Breezula) for hair loss treatment, noting that COVID-19 delayed female trials by three months but Phase III trials for males are proceeding with a Special Protocol Assessment filed with the FDA. Users express hope for Breezula as an alternative to existing treatments like finasteride and minoxidil, despite concerns about its potential high cost.
The user has been using Minoxidil, finasteride, and a dermaroller for a year with little effect on hair loss. They are considering a hair transplant and are questioning the number of grafts needed and the feasibility of transplanting onto a partially bald scalp.
A 22-year-old male with hair loss is considering treatments like finasteride, minoxidil, and derma rolling after being diagnosed with MPB, vitamin D deficiency, and dandruff. He seeks advice on whether these treatments can realistically improve his hair density and achieve a healthier NW2.
Scalp Botox may help hair loss by relaxing muscles and increasing blood flow, potentially benefiting conditions other than androgenetic alopecia. DHT affects hair follicles differently, causing tension and hair loss in some areas but not others.
A user shared their positive experience with a clinical trial for a new oral medication, VDPHL01, which is a reformulated version of oral minoxidil taken at a high dose of 17mg daily, showing significant hair regrowth after six months. The user noted that this formulation is believed to be more effective and time-released, with fewer side effects compared to regular oral minoxidil.
The conversation is about the potential side effects of using verteporfin in conjunction with a hair transplant. Specific treatments discussed include verteporfin, a hair transplant (HT), minoxidil (Min), finasteride (Fin), and RU58841 (RU).
A woman experiencing hormonal hair loss is on dutasteride and bicalutamide, which initially improved her hair, but she is now experiencing a second shedding phase with significant short hair loss. Despite normal hormone levels and no deficiencies, she is unsure if this shedding is normal and seeks advice.
The user is experiencing rapid hair loss despite using dutasteride, finasteride, and minoxidil, and is concerned about high estradiol and testosterone levels. They are advised to consult an endocrinologist for potential hormonal imbalances.
Bimatoprost 1% and 3% solutions showed better hair regrowth than minoxidil 5%. The user plans to test a homemade bimatoprost solution on their scalp and share results.
The conversation is about testing the effectiveness of RU58841 for hair loss, with the user planning to increase their dose to 30 mg per day along with 20 mg of Minoxidil. The test results showed approximately 70 mg/ml, which the user considers a good result.